Loading...
Loading...
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc. Spoken Alpha tracks BDRX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks BDRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BDRX.
curl https://api.spokenalpha.com/v1/companies/BDRX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.62 | $2.42 | +8.1% | -7.1% | -8.9% |
| Q4 FY2026 | $2.73 | $2.39 | +14.2% | -3.2% | -5.2% |
| Q3 FY2026 | $2.98 | $2.56 | +16.5% | -7.4% | -10.0% |
| Q2 FY2026 | $2.97 | $2.61 | +13.9% | -0.2% | +0.3% |
| Q1 FY2025 | $2.87 | $2.61 | +9.9% | -6.3% | -5.5% |
| Q4 FY2025 | $3.04 | $2.56 | +18.9% | -6.4% | -7.4% |
| Q3 FY2025 | $2.76 | $2.48 | +11.2% | +2.8% | +4.2% |
| Q2 FY2025 | $2.80 | $2.62 | +6.8% | -3.8% | -6.3% |
| Q1 FY2024 | $3.11 | $2.71 | +14.8% | +2.5% | +1.2% |
| Q4 FY2024 | $3.03 | $2.71 | +11.7% | -1.9% | -0.2% |